Association Between F-SIRI and Adverse Prognosis in Patients With Chronic Heart Failure

IF 2.3 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Clinical Cardiology Pub Date : 2025-06-16 DOI:10.1002/clc.70166

Xiaoli Liu, Heyu Chu, Guo Song, Yi Wang, Junfeng Duan, Xi Tan, Xue Bao, Biao Xu, Rong Gu

{"title":"Association Between F-SIRI and Adverse Prognosis in Patients With Chronic Heart Failure","authors":"Xiaoli Liu, Heyu Chu, Guo Song, Yi Wang, Junfeng Duan, Xi Tan, Xue Bao, Biao Xu, Rong Gu","doi":"10.1002/clc.70166","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aims</h3>\n \n <p>High plasma fibrinogen and systemic inflammation response index (F-SIRI) has been proposed as a novel prognostic factor in resectable gastric cancer. However, available data on the prognostic value of F-SIRI in chronic heart failure (CHF) patients is limited. We aimed to conduct a retrospective cohort study exploring the correlation between F-SIRI and prognosis in CHF individuals.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We consecutively enrolled 1589 hospitalized patients (aged 66 ± 8 years, 32.9% women) with CHF from January 1, 2019 to August 31, 2022 in this single-center retrospective study. SIRI was calculated with the formula (monocyte count*neutrophil count/lymphocyte count). The primary endpoints encompassed all-cause death, the major adverse cardiac and cerebral events (MACCEs) and cardiovascular death. The association between F-SIRI and the risk of developing adverse outcomes were explored using four multivariate-adjusted Cox proportional hazard models.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>During a median follow-up of 687 days, 207 all-cause deaths, 462 MACCEs and 136 cardiovascular deaths were recorded. After adjusting for potential confounding factors, only risk of all-cause death remained significantly associated with higher levels of F-SIRI. The hazard ratios (HRs) for the highest F-SIRI group (F-SIRI = 2) versus the lowest F-SIRI group (F-SIRI = 0) were 2.37 (95% confidence interval [CI], 1.46−3.83; <i>p</i> < 0.001) for all-cause death. The addition of F-SIRI could increase the prognostic ability for all-cause death on the basis of traditional risk factors.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>F-SIRI is a significant predictor of all-cause death but has limited predictive value for MACCEs and cardiovascular death in CHF patients.</p>\n </section>\n </div>","PeriodicalId":10201,"journal":{"name":"Clinical Cardiology","volume":"48 6","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clc.70166","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Cardiology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/clc.70166","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Aims

High plasma fibrinogen and systemic inflammation response index (F-SIRI) has been proposed as a novel prognostic factor in resectable gastric cancer. However, available data on the prognostic value of F-SIRI in chronic heart failure (CHF) patients is limited. We aimed to conduct a retrospective cohort study exploring the correlation between F-SIRI and prognosis in CHF individuals.

Methods

We consecutively enrolled 1589 hospitalized patients (aged 66 ± 8 years, 32.9% women) with CHF from January 1, 2019 to August 31, 2022 in this single-center retrospective study. SIRI was calculated with the formula (monocyte count*neutrophil count/lymphocyte count). The primary endpoints encompassed all-cause death, the major adverse cardiac and cerebral events (MACCEs) and cardiovascular death. The association between F-SIRI and the risk of developing adverse outcomes were explored using four multivariate-adjusted Cox proportional hazard models.

Results

During a median follow-up of 687 days, 207 all-cause deaths, 462 MACCEs and 136 cardiovascular deaths were recorded. After adjusting for potential confounding factors, only risk of all-cause death remained significantly associated with higher levels of F-SIRI. The hazard ratios (HRs) for the highest F-SIRI group (F-SIRI = 2) versus the lowest F-SIRI group (F-SIRI = 0) were 2.37 (95% confidence interval [CI], 1.46−3.83; p < 0.001) for all-cause death. The addition of F-SIRI could increase the prognostic ability for all-cause death on the basis of traditional risk factors.

Conclusions

F-SIRI is a significant predictor of all-cause death but has limited predictive value for MACCEs and cardiovascular death in CHF patients.

Abstract Image

查看原文本刊更多论文

慢性心力衰竭患者F-SIRI与不良预后的关系

目的高血浆纤维蛋白原和全身炎症反应指数（F-SIRI）被认为是可切除胃癌的一个新的预后因素。然而，关于F-SIRI在慢性心力衰竭（CHF）患者中的预后价值的现有数据有限。我们旨在开展一项回顾性队列研究，探讨心力衰竭患者F-SIRI与预后之间的相关性。方法2019年1月1日至2022年8月31日，我们在这项单中心回顾性研究中连续招募了1589例住院的CHF患者（年龄66±8岁，32.9%为女性）。SIRI计算公式为（单核细胞计数*中性粒细胞计数/淋巴细胞计数）。主要终点包括全因死亡、主要心脏和大脑不良事件（MACCEs）和心血管死亡。使用四个多变量校正Cox比例风险模型探讨F-SIRI与不良结局风险之间的关系。结果在687天的中位随访期间，记录了207例全因死亡、462例MACCEs和136例心血管死亡。在调整了潜在的混杂因素后，只有全因死亡的风险仍然与较高的F-SIRI水平显著相关。最高F-SIRI组（F-SIRI = 2）与最低F-SIRI组（F-SIRI = 0）的风险比（hr）为2.37(95%可信区间[CI]， 1.46−3.83；P < 0.001)。在传统危险因素的基础上，添加F-SIRI可提高全因死亡的预后能力。结论F-SIRI是全因死亡的重要预测因子，但对CHF患者MACCEs和心血管死亡的预测价值有限。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Cardiology 医学-心血管系统

CiteScore

5.10

自引率

3.70%

发文量

189

审稿时长

4-8 weeks

期刊介绍： Clinical Cardiology provides a fully Gold Open Access forum for the publication of original clinical research, as well as brief reviews of diagnostic and therapeutic issues in cardiovascular medicine and cardiovascular surgery. The journal includes Clinical Investigations, Reviews, free standing editorials and commentaries, and bonus online-only content. The journal also publishes supplements, Expert Panel Discussions, sponsored clinical Reviews, Trial Designs, and Quality and Outcomes.